Journal of Diabetes Investigation最新文献

筛选
英文 中文
Use of automated insulin delivery during major surgery in patients with type 1 diabetes: Two case reports. 在1型糖尿病患者的大手术中使用自动胰岛素输送:2例报告
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-12-12 DOI: 10.1111/jdi.14379
Julia Stadnik, Sebastian Seget, Mateusz Tarasiewicz, Przemysława Jarosz-Chobot, Karolina Piątek, Maria Dróżdż, Agnieszka Czarniecka, Tomasz Koszutski, Anna Walęza-Widuch, Krzysztof Olejnik, Bogdan Nowiński
{"title":"Use of automated insulin delivery during major surgery in patients with type 1 diabetes: Two case reports.","authors":"Julia Stadnik, Sebastian Seget, Mateusz Tarasiewicz, Przemysława Jarosz-Chobot, Karolina Piątek, Maria Dróżdż, Agnieszka Czarniecka, Tomasz Koszutski, Anna Walęza-Widuch, Krzysztof Olejnik, Bogdan Nowiński","doi":"10.1111/jdi.14379","DOIUrl":"https://doi.org/10.1111/jdi.14379","url":null,"abstract":"<p><p>With the rapid advancement of diabetes technology, the number of patients with type 1 diabetes (T1D) using automated insulin delivery (AID) systems is increasing, making the presence of such patients in the perioperative period more common. This study presents two cases of T1D patients who underwent thyroidectomy while using AID, following a protocol designed in collaboration with the diabetology, anesthesiology, and surgical teams. Two female patients, aged 12 and 33 years, both using AID systems, were admitted for elective thyroidectomy. Glycemic metrics prior to surgery indicated good glycemic control, leading to the decision to continue AID during the procedures. The use of AID enabled safe surgical performance with satisfactory glycemic control. In one case, a continuous glucose monitoring (CGM) sensor disruption likely resulted from acetaminophen distribution and/or sensor's proximity to the surgical field. This report highlights the need for standardized guidelines regarding the use of AID in the perioperative period.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity. 胰高血糖素样肽-1受体激动剂为下丘脑肥胖提供了新的治疗选择。
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-12-11 DOI: 10.1111/jdi.14372
Wanlu Ma, Bo Zhang, Xiaoping Chen
{"title":"Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity.","authors":"Wanlu Ma, Bo Zhang, Xiaoping Chen","doi":"10.1111/jdi.14372","DOIUrl":"https://doi.org/10.1111/jdi.14372","url":null,"abstract":"<p><p>We briefly summarizes the mechanism of GLP-1RA therapy in HO both in rodents and in humans. We also summarized the clinical trials and case reports of GLP-1RA therapy in HO, especially the more and more often used semaglutide. We are hoping the therapy of GLP-1RA in HO will arouse more attention from clinicians in the future.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maximum insulin dose in patients admitted to the intensive care units with severe COVID-19 in the "Cross ICU Searchable Information System" study: A multicenter retrospective cohort study. “跨ICU可检索信息系统”研究重症监护病房重症COVID-19患者的最大胰岛素剂量:一项多中心回顾性队列研究
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-12-10 DOI: 10.1111/jdi.14380
Emi Ushigome, Dan Imai, Masahide Hamaguchi, Satoru Hashimoto, Michiaki Fukui
{"title":"Maximum insulin dose in patients admitted to the intensive care units with severe COVID-19 in the \"Cross ICU Searchable Information System\" study: A multicenter retrospective cohort study.","authors":"Emi Ushigome, Dan Imai, Masahide Hamaguchi, Satoru Hashimoto, Michiaki Fukui","doi":"10.1111/jdi.14380","DOIUrl":"https://doi.org/10.1111/jdi.14380","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to determine the maximum daily insulin dose (MDI) and associated factors in critically ill patients with coronavirus disease 2019 (COVID-19) receiving insulin therapy, under ventilator and/or extracorporeal membrane oxygenation (ECMO) management.</p><p><strong>Materials and methods: </strong>This cross-sectional analysis used the Cross ICU Searchable Information System data from a Japanese multicenter retrospective observational cohort study of critically ill patients with COVID-19 receiving ventilation and/or ECMO, from February 2020 to March 2022. Maximum daily insulin dose was determined, and factors associated with it and maximum daily insulin dose per body weight were assessed using linear regression analysis.</p><p><strong>Results: </strong>The analysis included 788 patients. Their mean age, glycated hemoglobin level, maximum daily insulin dose, and time from admission to the maximum daily insulin dose were 65.2 ± 13.0 years, 7.0 ± 1.5% (53.0 ± 7.1 mmol/mol), 46.0 ± 43.6 U/day, and 7.3 ± 7.0 days, respectively. Male sex (β = 6.902, P = 0.034), body mass index (β = 1.020, P = 0.001), glycated hemoglobin (β = 12.272, P < 0.001), and having renal failure (β = 20.637, P = 0.003) were independent determinants of maximum daily insulin dose. Age (β = 0.004, P = 0.035), glycated hemoglobin (β = 0.154, P < 0.001), and having renal failure (β = 0.282, P = 0.004) were independent determinants of maximum daily insulin dose per body weight.</p><p><strong>Conclusions: </strong>In patients with COVID-19 on ventilator and/or ECMO management, the maximum daily insulin dose reached after about 1 week of hospitalization was approximately 46.0 U/day. Glycated hemoglobin and renal failure were both associated with the maximum daily insulin dose and maximum daily insulin dose per body weight.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polyethylene glycol loxenatide modulates lipid metabolism and insulin resistance through lncRNA steroid receptor RNA activator/cellular nucleic acid binding protein/Rho-associated coiled-coil kinase 2 axis in type 2 diabetes mellitus. 聚乙二醇洛xenatide通过lncRNA类固醇受体RNA激活剂/细胞核酸结合蛋白/ rho相关卷曲激酶2轴调节2型糖尿病脂质代谢和胰岛素抵抗。
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-12-09 DOI: 10.1111/jdi.14373
Zhuangsen Chen, Zhongyu Zhou, Lin Wang, Yanrong Zhang, Caiyan Huang, Cong Wang, Ying Huang, Shanshan Wang, Dewen Yan, Kun Feng
{"title":"Polyethylene glycol loxenatide modulates lipid metabolism and insulin resistance through lncRNA steroid receptor RNA activator/cellular nucleic acid binding protein/Rho-associated coiled-coil kinase 2 axis in type 2 diabetes mellitus.","authors":"Zhuangsen Chen, Zhongyu Zhou, Lin Wang, Yanrong Zhang, Caiyan Huang, Cong Wang, Ying Huang, Shanshan Wang, Dewen Yan, Kun Feng","doi":"10.1111/jdi.14373","DOIUrl":"https://doi.org/10.1111/jdi.14373","url":null,"abstract":"<p><strong>Background: </strong>Polyethylene glycol loxenatide (PEG-Loxe) is applied in treating type 2 diabetes mellitus. Nevertheless, the effect and mechanism of PEG-Loxe on lipid metabolism disorder and insulin resistance in type 2 diabetes mellitus are not fully understood.</p><p><strong>Methods: </strong>Type 2 diabetes mellitus rats developed by high-fat diet/streptozotocin injection were treated with PEG-Loxe (0.3 or 1 mg/kg). Insulin resistance was evaluated by fasting blood glucose (FBG), oral glucose tolerance test, fasting insulin, homeostasis model of assessment for insulin resistance and for insulin sensitivity. Immunohistochemistry, hematoxylin and eosin staining, and biochemistry measurements were performed to assess lipid metabolism. Inflammatory response and oxidative stress were assessed by inflammatory cytokines and reactive oxygen species. Genes' expressions were tested using RT-qPCR, western blot, and in situ hybridization. Relationships of molecules were validated by pull-down assay and RNA immunoprecipitation. mRNA stability was examined by actinomycin D assay.</p><p><strong>Results: </strong>High-PEG-Loxe decreased FBG and ameliorated glucose tolerance, hyperinsulinemia, and insulin resistance. Low-PEG-Loxe partly while high-PEG-Loxe apparently relieved hepatocyte injury, reduced lipase I, triglyceride, total cholesterol and leptin, and increased adiponectin in type 2 diabetes mellitus rats. PEG-Loxe mitigated inflammatory response and oxidative stress. High-PEG-Loxe reduced RhoA and Rho-associated coiled-coil kinase 2 (ROCK2) in liver tissues of type 2 diabetes mellitus rats, while both doses of PEG-Loxe decreased steroid receptor RNA activator (SRA). SRA overexpression reversed the protective functions of high-PEG-Loxe. SRA cooperated with cellular nucleic acid binding protein (CNBP) to enhance ROCK2 mRNA stability.</p><p><strong>Conclusion: </strong>High-PEG-Loxe relieves insulin resistance and lipid metabolism disorder in type 2 diabetes mellitus through SRA/CNBP/ROCK2 axis. This research provides a molecular mechanism of PEG-Loxe for treating type 2 diabetes mellitus.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142798815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Placental expression of GLUT-1, GLUT-3, and GLUT-4 mRNA and transcriptome profiling in pregnant women with diabetes. 妊娠糖尿病患者胎盘中GLUT-1、GLUT-3和GLUT-4 mRNA的表达及转录组分析
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-12-09 DOI: 10.1111/jdi.14369
Rafal Sibiak, Pawel Gutaj, Urszula Mantaj, Lukasz Adamczak, Malgorzata Blatkiewicz, Marcin Rucinski, Ewa Wender-Ozegowska
{"title":"Placental expression of GLUT-1, GLUT-3, and GLUT-4 mRNA and transcriptome profiling in pregnant women with diabetes.","authors":"Rafal Sibiak, Pawel Gutaj, Urszula Mantaj, Lukasz Adamczak, Malgorzata Blatkiewicz, Marcin Rucinski, Ewa Wender-Ozegowska","doi":"10.1111/jdi.14369","DOIUrl":"https://doi.org/10.1111/jdi.14369","url":null,"abstract":"<p><strong>Aims/introduction: </strong>Placental glucose transport is regulated by glucose transporter proteins (GLUTs). The study aimed to examine placental expression of GLUT-1, GLUT-3, and GLUT-4 mRNA in patients with type 1 diabetes, early gestational diabetes (eGDM), and healthy controls, and to investigate correlations between GLUTs expression and clinical parameters. Additionally, we compared placental transcriptome profiles in recruited subgroups.</p><p><strong>Materials and methods: </strong>We recruited 59 pregnant women: 23 with type 1 diabetes, 17 with eGDM, and 19 controls. Patients with diabetes attended follow-up visits at each trimester. Transcriptome studies were performed in 4 patients per subgroup.</p><p><strong>Results: </strong>The mean age was similar across all subgroups. eGDM patients had significantly higher BMI and were predominantly obese. We observed a significant 2-fold (P = 0.009) decrease in placental GLUT-3 mRNA expression in the type 1 diabetes and eGDM groups. GLUT-4 mRNA expression was significantly lower in the eGDM group compared to type 1 diabetes (3-fold) and controls (6-fold) (P = 0.007). There was a significant negative correlation between GLUT-3 (R = -0.29) and GLUT-4 (R = -0.27) mRNA expression and neonatal birth weight. GLUT-4 expression was negatively correlated with 1st trimester HbA1c (R = -0.72) and OGTT 120' (R = -0.82) results in eGDM patients, and 3rd trimester glycemic variability (R = -0.49) in type 1 diabetes. Microarray analysis revealed significant transcriptomic changes, with 45 down-regulated and 365 up-regulated genes in type 1 diabetes, and 21 significant changes in eGDM.</p><p><strong>Conclusions: </strong>Placental samples from patients with diabetes exhibit changes in GLUTs expression, which correlates with neonatal growth and several glycemic parameters. Additionally, multiple changes in transcriptomic profiles are observed in hyperglycemic patients.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142798814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of universal screening for gestational diabetes mellitus between one-step and two-step method among Thai pregnant women: A randomized control trial. 泰国孕妇妊娠糖尿病普查一步法与两步法的比较:随机对照试验。
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-11-28 DOI: 10.1111/jdi.14370
Natthaphon Phoblap, Phudit Jatavan, Theera Tongsong
{"title":"Comparison of universal screening for gestational diabetes mellitus between one-step and two-step method among Thai pregnant women: A randomized control trial.","authors":"Natthaphon Phoblap, Phudit Jatavan, Theera Tongsong","doi":"10.1111/jdi.14370","DOIUrl":"https://doi.org/10.1111/jdi.14370","url":null,"abstract":"<p><strong>Aims: </strong>To compare the prevalence of GDM and pregnancy outcomes between the one-step and two-step methods of universal screening among Thai pregnant women.</p><p><strong>Methods: </strong>A randomized controlled trial was conducted on singleton Thai pregnant women at a gestational age of 24-28 weeks. They were randomly assigned to either the one-step method group (a universal 75-gm 2-h oral glucose tolerance test: OGTT) or the two-step method group (a universal 50-gm oral glucose challenge test followed by a 100-gm 3-h OGTT). The women received standard antenatal care. The prevalence of GDM and obstetric outcomes were compared.</p><p><strong>Results: </strong>A total of 143 women meeting the inclusion criteria were randomly allocated into the one-step group (72 cases) and the two-step group (71 cases). The prevalence of GDM was significantly higher in the one-step group than in the two-step group, with rates of 24/73 (33.3%) vs 8/70 (11.3%); P value 0.002; relative risk of 2.96, 95% CI: 1.43-6.14, respectively. Demographic data and maternal and neonatal outcomes were comparable between the two groups.</p><p><strong>Conclusions: </strong>The one-step method can markedly increase the prevalence of GDM to nearly three times that of the two-step method, leading to a substantial increase in care costs and burdens without clear benefits. Convincingly, the one-step method as a new approach may not be suitable for universal screening in a busy antenatal care setting, especially in low-resource health centers in developing countries or among populations with a high prevalence of GDM.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment. 通过短期持续皮下胰岛素输注强化治疗结合低碳水化合物饮食治疗新诊断的2型糖尿病的缓解。
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-11-28 DOI: 10.1111/jdi.14371
Xuemei Huang, Jiajin Jiang, Li Liu, Yuanyuan Lin, Feng Zhang, Xiaoshan Ling, Haitao Wei, Guangjing Huang, Jinqun Ye, Cen Huang, Jianli Huang, Wenfu Tao, Xinyu Zou
{"title":"Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment.","authors":"Xuemei Huang, Jiajin Jiang, Li Liu, Yuanyuan Lin, Feng Zhang, Xiaoshan Ling, Haitao Wei, Guangjing Huang, Jinqun Ye, Cen Huang, Jianli Huang, Wenfu Tao, Xinyu Zou","doi":"10.1111/jdi.14371","DOIUrl":"https://doi.org/10.1111/jdi.14371","url":null,"abstract":"<p><strong>Aim/introduction: </strong>To evaluate the therapeutic efficacy short-term continuous subcutaneous insulin infusion (CSII) intensive therapy combined with a low-carbohydrate diet (LCD) for diabetes remission in patients with newly diagnosed type 2 diabetes mellitus.</p><p><strong>Materials and methods: </strong>This study included patients newly diagnosed with type 2 diabetes mellitus, who were randomly divided into two groups: conventional (conventional CSII + traditional lifestyle guidance); and intensive (intensive CSII + LCD lifestyle guidance). CSII was used for blood glucose control, with continuous glucose monitoring (CGM) used to monitor blood glucose levels. The primary outcome measure was hemoglobin A1c (HbA1c) level; secondary outcomes included body weight, body mass index (BMI), waist circumference, glycemic control, and biochemical indices.</p><p><strong>Results: </strong>The time in range (TIR) in the intensive treatment group was greater than that in the conventional treatment group (P < 0.05). There was no significant difference in the incidence of hypoglycemia between the two groups (P > 0.05). Compared with the conventional treatment group, diabetes remission rates were significantly greater in the intensive treatment group (P < 0.05). In the intensive treatment group, fasting plasma glucose (FPG), HbA1c, Homeostasis Model assessment of Insulin Resistance (HOMA-IR), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), and changes in body weight, BMI, visceral fat area (VFA), and subcutaneous fat area (SFA) decreased significantly (P < 0.05). FPG, HOMA-IR, TG, LDL-c, and changes in body weight, BMI, waist circumference, and VFA were significantly correlated with HbA1c levels (P < 0.05).</p><p><strong>Conclusions: </strong>The combination of intensive CSII and LCD lifestyle guidance had been improved the remission rate in patients with newly diagnosed type 2 diabetes mellitus.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gestational diabetes in early pregnancy is associated with postpartum glucose intolerance: A perspective from the diabetes and pregnancy outcome for mother and baby study in Japan. 妊娠早期妊娠糖尿病与产后葡萄糖耐受不良相关:来自日本糖尿病与妊娠结局的母婴研究
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-11-28 DOI: 10.1111/jdi.14368
Maki Yokoyama, Kei Miyakoshi, Noriyuki Iwama, Hiroshi Yamashita, Ichiro Yasuhi, Maki Kawasaki, Naoko Arata, Shiori Sato, Yuko Imura, Masako Waguri, Haruna Kawaguchi, Naoki Masaoka, Yoshiyuki Nakajima, Yuji Hiramatsu, Takashi Sugiyama
{"title":"Gestational diabetes in early pregnancy is associated with postpartum glucose intolerance: A perspective from the diabetes and pregnancy outcome for mother and baby study in Japan.","authors":"Maki Yokoyama, Kei Miyakoshi, Noriyuki Iwama, Hiroshi Yamashita, Ichiro Yasuhi, Maki Kawasaki, Naoko Arata, Shiori Sato, Yuko Imura, Masako Waguri, Haruna Kawaguchi, Naoki Masaoka, Yoshiyuki Nakajima, Yuji Hiramatsu, Takashi Sugiyama","doi":"10.1111/jdi.14368","DOIUrl":"https://doi.org/10.1111/jdi.14368","url":null,"abstract":"<p><strong>Aims: </strong>To compare perinatal outcomes and postpartum glucose tolerance between women diagnosed with gestational diabetes mellitus (GDM) before 20 weeks of gestation (EGDM) and those diagnosed at or after 24 weeks of gestation (LGDM) in a Japanese population.</p><p><strong>Materials and methods: </strong>Data were obtained from a prospective GDM registry. Multivariate analysis was conducted to examine the association between the timing of GDM diagnosis (EGDM vs LGDM) and perinatal outcomes (preterm birth, small for gestational age, large for gestational age, pregnancy-induced hypertension, and neonatal hypoglycemia), as well as postpartum glucose intolerance.</p><p><strong>Results: </strong>A total of 1,275 mother-infant pairs were analyzed for perinatal outcomes. Of these, 924 women underwent postpartum testing for glucose intolerance. No significant differences in perinatal outcomes were observed between the EGDM and LGDM groups, except that overweight/obese women with EGDM had 2.5-fold higher rate of preterm birth than those with LGDM. Postpartum glucose intolerance was 1.5 times more likely in the EGDM group than in the LGDM group.</p><p><strong>Conclusions: </strong>Women with EGDM had a significantly higher risk of postpartum glucose intolerance than those with LGDM, despite similar perinatal outcomes between the two groups.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toward a cure for diabetes: iPSC and ESC-derived islet cell transplantation trials. 治疗糖尿病:iPSC 和源自 ESC 的胰岛细胞移植试验。
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2024-11-22 DOI: 10.1111/jdi.14366
Junji Fujikura, Takayuki Anazawa, Taro Toyoda, Ryo Ito, Yasuko Kimura, Daisuke Yabe
{"title":"Toward a cure for diabetes: iPSC and ESC-derived islet cell transplantation trials.","authors":"Junji Fujikura, Takayuki Anazawa, Taro Toyoda, Ryo Ito, Yasuko Kimura, Daisuke Yabe","doi":"10.1111/jdi.14366","DOIUrl":"https://doi.org/10.1111/jdi.14366","url":null,"abstract":"<p><p>Advancements in regenerative medicine, particularly through the use of induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), are garnering substantial attention as potential solutions to the limited availability of donors, leading to prolonged waiting periods for people with type 1 diabetes who require transplantation of pancreatic islets from deceased donors. The promising outcomes from recent clinical trials suggest that transplantation of iPSC- or ESC-derived islet cells could pave the way for more effective and broadly accessible treatment options. This progress holds potential not only for individuals with type 1 diabetes but may also extend to type 2 diabetes treatment in the future.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142685532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine learning for the prediction of atherosclerotic cardiovascular disease during 3-year follow up in Chinese type 2 diabetes mellitus patients 机器学习在中国型动脉粥样硬化性心血管疾病3年随访中的预测 2例糖尿病患者。
IF 3.2 3区 医学
Journal of Diabetes Investigation Pub Date : 2023-08-22 DOI: 10.1111/jdi.14069
Jinru Ding, Yingying Luo, Huwei Shi, Ruiyao Chen, Shuqing Luo, Xu Yang, Zhongzhou Xiao, Bilin Liang, Qiujuan Yan, Jie Xu, Linong Ji
{"title":"Machine learning for the prediction of atherosclerotic cardiovascular disease during 3-year follow up in Chinese type 2 diabetes mellitus patients","authors":"Jinru Ding,&nbsp;Yingying Luo,&nbsp;Huwei Shi,&nbsp;Ruiyao Chen,&nbsp;Shuqing Luo,&nbsp;Xu Yang,&nbsp;Zhongzhou Xiao,&nbsp;Bilin Liang,&nbsp;Qiujuan Yan,&nbsp;Jie Xu,&nbsp;Linong Ji","doi":"10.1111/jdi.14069","DOIUrl":"10.1111/jdi.14069","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>Clinical guidelines for the management of individuals with type 2 diabetes mellitus endorse the systematic assessment of atherosclerotic cardiovascular disease risk for early interventions. In this study, we aimed to develop machine learning models to predict 3-year atherosclerotic cardiovascular disease risk in Chinese type 2 diabetes mellitus patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Clinical records of 4,722 individuals with type 2 diabetes mellitus admitted to 94 hospitals were used. The features included demographic information, disease histories, laboratory tests and physical examinations. Logistic regression, support vector machine, gradient boosting decision tree, random forest and adaptive boosting were applied for model construction. The performance of these models was evaluated using the area under the receiver operating characteristic curve. Additionally, we applied SHapley Additive exPlanation values to explain the prediction model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All five models achieved good performance in both internal and external test sets (area under the receiver operating characteristic curve &gt;0.8). Random forest showed the highest discrimination ability, with sensitivity and specificity being 0.838 and 0.814, respectively. The SHapley Additive exPlanation analyses showed that previous history of diabetic peripheral vascular disease, older populations and longer diabetes duration were the three most influential predictors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The prediction models offer opportunities to personalize treatment and maximize the benefits of these medical interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 11","pages":"1289-1302"},"PeriodicalIF":3.2,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信